LENSAR, Inc. (LNSR) Reports Q3 Loss of $0.64
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update
November 9, 2020 4:01 PM ESTProcedure Numbers Consistent with 2019 Levels
Cash and Cash Equivalents of $42.7 Million as of September 30, 2020
ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (NASDAQ: LNSR) (LENSAR or the Company), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the third quarter ended September 30, 2020 and provided an update on key strategic and operational initiatives. The distribution of LENSAR common stock to stockholders of PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) took... More
